Skip to main content

Table 1 Preoperative characteristics of 210 patients with ARDS after cardiac surgery grouped by CPB time

From: Association between cardiopulmonary bypass time and mortality among patients with acute respiratory distress syndrome after cardiac surgery

 

Total

Non-CPB

Short CPB time

Long CPB time

P value

Demographic data

     

n (%)

210

55 (26.2)

77 (36.7)

78 (37.1)

 

Age (years), mean ± SD

58.5 ± 13.6

65.7 ± 10.7

57.9 ± 13.3a

54.1 ± 13.8b

< 0.001

Male, n (%)

140 (66.7)

35 (63.6)

46 (59.7)

59 (75.6)

0.135

BMI (kg/m2), mean ± SD

24.7 ± 4.1

25.3 ± 3.5

23.7 ± 4.3

25.3 ± 4.1c

0.016

Comorbidities, n (%)

     

Smoking, n (%)

80 (38.1)

22 (40.0)

23 (29.9)

35 (44.9)

0.149

 Hypertension

114 (54.3)

31 (56.4)

31 (40.3)

52 (66.7)c

0.004

 Diabetes mellitus

44 (21)

22 (40.0)

10 (13.0)a

12 (15.4)b

< 0.001

 Cerebrovascular disease

27 (12.9)

8 (14.5)

11 (14.3)

8 (10.3)

0.687

 Chronic lung disease

14 (6.7)

5 (9.1)

3 (3.9)

6 (7.7)

0.449

 Coronary heart disease

87 (41.1)

38 (69.1)

21 (27.3) a

28 (35.9) b

< 0.001

 Valve disease

27 (12.9)

0 (0)

17 (22.1)

10 (12.8)

< 0.001

Preoperative LVEF (%), mean ± SD

60.5 ± 8.9

60.2 ± 8.7

58.8 ± 10.1

62.5 ± 7.4c

0.031

NYHA grade III-IV, n (%)

75 (35.7)

23 (41.8)

30 (39.0)

22 (28.2)

0.206

Preoperative drug therapy, n (%)

     

 ACEI

62 (29.5)

25 (45.5)

16 (20.8)a

21 (26.9)

0.007

 Beta-blocker

111 (52.9)

41(74.5)

35 (45.5)a

35 (44.9)b

0.001

 CCB

64 (30.5)

17 (30.9)

21 (27.3)

26 (33.3)

0.712

 Aspirin

24 (11.4)

15 (27.3)

5 (6.5)a

4 (5.1)b

< 0.001

 Statins

68 (32.4)

31 (56.4)

19 (24.7)

18 (23.1)

< 0.001

Surgery type, n (%)

    

< 0.001

 CABG

65 (31.1)

52 (94.5)

7 (9.1)a

6 (7.8)b

< 0.001

 Valve replacement

65 (31.1)

0 (0)

42 (54.5) a

23 (29.9) b,c

< 0.001

 Ascending aorta replacement

69 (33.0)

2 (3.6)

22 (28.6) a

45 (58.4) b,c

< 0.001

 Other

10 (4.8)

1 (1.8)

6 (7.8)

3 (3.9)

0.252

Emergency surgery

51

9

16

26

< 0.001

Operation time (h), mean ± SD

6.2 ± 2.7

4.5 ± 1.5

5.4 ± 1.8a

8.1 ± 3.0b,c

< 0.001

Aortic clamping time (min)

median (IQR)

79.0 (0-116.5)

0

79.0 (62.5–100.0)a

126.5 (101.2-159.3)b,c

< 0.001

Blood loss, (mL)

800

(600–1500)

600

(400–900)

800

(600–1000)

1200

(800–1800)b,c

< 0.001

RBC infusion (U)

12 (6–20)

6.0 (4.0–12.0)

12.0 (6.0-18.5)a

16.0(8.0–24.0) b

< 0.001

FFP infusion (mL)

800 (200–1600)

400 (200–1000)

800 (300–1600)a

1000 (400–2050)b

0.001

PLT infusion (U)

0 (0–4)

0 (0–2)

0 (0–4)a

2 (0–4)b

< 0.001

  1. a Non CPB vs. short CPB time, P < 0.05; b short CPB time vs. long CPB time (CPB 173 ≥ minutes), P < 0.05; c non CPB vs. long CPB time, P < 0.05; Short CPB time = 0 < CPB < 173 min, long CPB time = CPB 173 ≥ minutes
  2. LVEF = left ventricular ejection fraction, NYHA = New York Heart Association, ACEI = angiotensin converting enzyme inhibitor, CCB = calcium channel blocker, CABG = coronary artery bypass grafting, RBC = red blood cell, FFP = fresh frozen plasm
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us